RGS17 and prostate carcinoma: To test whether downregulation of RGS17 inhibited prostate cancer cell growth, we performed cell proliferation assays in the prostate cancer cells using siRNA against RGS17 and observed greatly reduced cell growth and viability when compared to the cells with control siRNAs (Fig. 6a, b).